Management of Infections Complicating Allogeneic Hematopoietic Stem Cell Transplantation

Seminars in Hematology

Volumn 46, Issue 3, 2009, Pages 289-312

  Hiemenz, John W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CARBAPENEM; CEPHALOSPORIN; CIDOFOVIR; CORTICOSTEROID; DAPTOMYCIN; FAMCICLOVIR; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; LINEZOLID; METHOTREXATE; METRONIDAZOLE; OSELTAMIVIR; PENICILLIN G; PLACEBO; POLIOMYELITIS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNINDEXED DRUG; VALACICLOVIR; VANCOMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ANTIFUNGAL RESISTANCE; ARTICLE; BACTERIAL INFECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; ENGRAFTMENT; ENVIRONMENTAL FACTOR; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; INFLUENZA; LIVING DONOR; LOW DRUG DOSE; MORBIDITY; MORTALITY; MYCOSIS; MYELOABLATIVE CONDITIONING; NONHUMAN; OPPORTUNISTIC INFECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLIOMYELITIS; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REDUCED INTENSITY CONDITIONING; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEPTIC SHOCK; SEROLOGY; STAPHYLOCOCCUS INFECTION; STEM CELL MOBILIZATION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; TREATMENT OUTCOME; VIRUS INFECTION;

BACTERIAL INFECTIONS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; TRANSPLANTATION, HOMOLOGOUS; VIRUS DISEASES;

EID: 67249096640     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2009.03.005     Document Type: Article

References (185)

1. Mengarelli A., Iori A., Guglielmi C., Romano A., Cerretti R., Torromeo C., et al. Standard versus alternative myeloablative conditioning regimens in allogeneic stem cell transplantation for high-risk acute leukemia. Hematologica 87 (2002) 52-58
2. Junghanass C., and Marr K.A. Infectious risks and outcomes after stem cell transplantation: are myeloablative transplants changing the picture?. Current Opin Infect Dis. 15 (2002) 347-353
3. Laughlin M.J., Eapen M., Rubinstein P., Wagner J.E., Zhang M.J., Champlin R.E., et al. Outcomes after transplantation of cord blood of bone marrow from unrelated donors. N Engl J Med. 351 (2004) 2265-2275
4. Takahashi S. Leukemia: cord blood for allogeneic stem cell transplantation. Curr Opin Oncol. 19 (2007) 667-672
5. Richard S., and Schuster M.W. Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 1 (2002) 103-109
6. Boeckh M., Garret W.G., Papanicolau G., Rubin R., Wingard J.R., and Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges and future strategies. Biol Blood Marrow Transplant 9 (2003) 543-558
7. Zerr D.M., Corey L., Kim H.W., Huang M.L., Nguy L., and Boeckh M. Clinical outcomes of human herpes virus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 40 (2005) 932-940
8. Deej H.J., Meyers J.D., Storb R., Graham T.C., and Weiden P.L. The effect of trimethoprim-sulfamethoxazole on hematological recovery after total body irradiation and autologous marrow infusion in dogs. Transplantation 28 (1979) 243-246
9. Jancel T., and Penzak P. Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia. Semin Hematol. (2009) (current issue)
10. Storek J., and Witherspoon R.P. Immunologic reconstitution after hematopoietic stem cell transplantation. In: Atkinson K. (Ed). Clinical bone marrow and blood stem cell transplantation. 2nd ed. (2000), Cambridge University Press, Cambridge, UK 111-146
11. Tayebi H., Tiberghien P., Ferrand C., Lienard A., Duperrier A., Cahn J.Y., et al. Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation. Bone Marrow Transplant 27 (2001) 167-175
12. Storek J., Witherspoon R.P., and Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 16 (1995) 413-425
13. Ashihara E., Shimazaki C., Yamagata N., Hirata T., Okawa K., Oku N., et al. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis. Bone Marrow Transplant 13 (1994) 377-381
14. Reittie J.E., Gottlieb D., Heslop H.E., Leger O., Drexler H.G., Hazlehurst G., et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after cytotoxic chemotherapy. Blood 73 (1989) 1351-1358
15. Atkinson K. Reconstruction of the haematopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 5 (1990) 202-226
16. Noel D.R., Witherspoon R.P., Storb R., Atkinson K., Doney K., Mickelson E.M., et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation?. An observation on long-term survivors. Blood 51 (1978) 1087-1105
17. Quinnan G.V., Kirmani N., Rook A.H., Manischewitz J.F., Jackson L., Moreschi G., et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med. 307 (1982) 7-13
18. Meyers J.D., Flournoy N., and Thomas E.D. Cell mediated immunity to varicella-zoster virus after allogeneic marrow transplant. J Infect Dis. 141 (1980) 479-487
19. Meyers J.D., Flournoy N., and Thomas E.D. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis. 142 (1980) 338-346
20. Witherspoon R.P., Deeg H.J., Lum L.G., Ochs H.D., Hansen J.A., Thomas E.D., and Storb R. Immunologic recovery in human marrow graft recipients given cyclosporine or methotrexate for the prevention of graft-versus-host disease. Transplantation 37 (1984) 456-461
21. Witherspoon R.P., Lum L.G., Storb R., and Thomas E.D. In vitro regulation of immunoglobulin synthesis after human marrow transplantation. Deficient T and non-T lymphocyte function within 3-4 months of allogeneic, syngeneic, or autologous marrow grafting for hematopoietic malignancy. Blood 59 (1982) 844-850
22. Atkinson K., Munro V., Vasak E., and Biggs J.C. Mononuclear cell populations in the skin defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. Br J Dermatol. 114 (1986) 145-160
23. Small T.N., Robinson W.H., and Miklos D.B. B cells and transplantation: an educational resource. Biol Blood Marrow Transplant 15 (2009) 104-113
24. Raaphorst F.M. Reconstitution of the B cell repertoire after bone marrow transplantation does not recapitulate human fetal development. Bone Marrow Transplant 24 (1999) 1267-1272
25. Winston D.J., Schiffman G., Wang D.C., Feig S.A., Lin C.H., Marso E.L., et al. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med. 91 (1979) 835-841
26. Norlin A.-C., Sairafi D., Mattsson J., Ljungman P., Ringden O., and Remberger M. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 41 (2008) 267-273
27. Storek J., Viganego F., Dawson M.A., Herremans M.M.P.T., Boeckh M., Flowers M.E.D., et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood 101 (2003) 3319-3324
28. Dykewicz C.A., Centers for Disease Control and Prevention (US), Infectious Diseases Society of America, and American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 33 (2001) 139-144
29. Ljungman P., Engelhard D., de la Camara R., Einsele H., Locasciulli A., Martino R., et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 35 (2005) 737-746
30. Winston D.J., Territo M.C., Ho W.G., Miller M.J., Gale R.P., and Golde D.W. Alveolar macrophage dysfunction in human bone marrow transplant recipients. Am J Med. 73 (1982) 859-866
31. Bentel J., and Atkinson K. Cytokine activity after human bone marrow transplantation: production of macrophage procoagulant activity and the T lymphokine regulating its production. Br J Haematol. 69 (1988) 181-187
32. Nachbaur D., Kircher B., Eisendle K., Latzer K., Haun M., and Gastl G. Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic stem cell transplantation. Br J Haematol. 123 (2003) 119-126
33. Penack O., Fischer L., Stroux A., Gentilini C., Nogal A., Muessig A., et al. A novel method to quantify and characterize leukemia-reactive natural killer cells in patients undergoing allogeneic stem cell transplantation following conventional or reduced dose conditioning. Int J Hematol. 85 (2007) 326-332
34. Kim D.H., Sohn S.K., Lee N.Y., Baek J.H., Kim J.G., Won D.I., et al. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. Eur J Haematol. 75 (2005) 299-308
35. Ho V.T., and Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98 (2001) 3192-3204
36. Wagner J.E., Thompson J.S., Carter S.L., and Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year survival in recipients of unrelated donor bone marrow (T-Cell Depletion Trial): a multi-center, randomized phase II-III trial. Lancet 366 (2005) 733-741
37. Novitzky N., Rubinstein R., Hallett J.M., du Toit C.E., and Thomas V.L. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myelogenous leukemia: a therapeutic strategy. Transplantation 69 (2000) 1358-1363
38. Cutler C., Giri S., Jeyapalan S., Paniagua D., Viswanathan A., and Antin J.H. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 19 (2001) 3685-3691
39. Junghanss C., and Marr K.A. Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?. Curr Opin Infect Dis. 15 (2002) 347-353
40. Ruiz-Argüelles G.J., Gómez-Almaguer D., López-Martínez B., Ponce-De-León S., Cantú-Rodriguez O.G., and Jaime-Pérez J.C. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 7 (2002) 95-99
41. Chakrabarti S., Mackinnon S., Chopra R., Kottaridis P.D., Peggs K., O'Gorman P., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99 (2002) 4357-4363
42. Anaissie E.J., Kontoyiannis D.P., O'Brien S., Kantarjian H., Robertson L., Lerner S., et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 129 (1998) 559-566
43. Samonis G., and Kontonyiannis D.P. Infectious complications of purine analog therapy. Curr Opin Infect Dis. 14 (2001) 409-413
44. Tam C.S., Wolf M.M., Januszewicz E.H., Grigg A.P., Prince H.M., Westerman D., et al. A new model for predicting infectious complications during fludarabine based combination chemotherapy among patients with indolent lymphoma. Cancer 101 (2004) 2042-2049
45. Greinix H.T., Fae I., Schneider B., Rosenmayr A., Mittershiffthaler A., Pelzmann B., et al. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant 35 (2005) 57-62
46. Schoemans H., Theunissen K., Maertens J., Boogaerts M., Verfaillie C., and Wagner J. Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant 38 (2006) 83-93
47. Eurocord, European Blood and Marrow Transplant Group, Rocha V., and Gluckman E. Clinical use of umbilical cord blood hematopoietic stem cells. Biol Blood Marrow Transplant 12 Suppl 1 (2006) 34-41
48. Laughlin M.J., Barker J., Bambach B., Koc O.N., Rizzieri D.A., Wagner J.E., et al. Hematopoietic survival and engraftment in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 344 (2001) 1815-1822
49. Barker J.N., Weisdorf D.J., DeFor T.E., Blazar B.R., McGlave P.B., Miller J.S., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
50. Viollier R., Socié G., Tichelli A., Bacigalupo A., Korthof E.T., Marsh J., et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 41 (2008) 45-50
51. US Department of Health and Human Services Advisory Council on Blood Stem Cell Transplantation (ACBSCT) January 28-29, 2008. http://bloodcell.transplant.hrsa.gov/ABOUT/Advisory_Council/Meetings/Notes/DOCS/ACBSCT_Summary_Notes_Jan2008.pdf Accessed February 20, 2009.
52. Grewal S.S., Barker J.N., Davies S.M., and Wagner J.E. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?. Blood 101 (2003) 4233-4244
53. Ljungman P., de la Camara R., Cordonnier C., Einsele H., Engelhard D., Reusser P., et al. European Conference on Infections in Leukemia. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 42 (2008) 227-240
54. Walker C.M., van Burik J.H., De For T.E., and Weisdorf D.J. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 13 (2007) 1106-1115
55. Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., and Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102 (2003) 4255-4260
56. Chemaly R.F., Gosh S., Bodey G.P., Rohatgi N., Safdar A., Keating M.J., et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 85 (2006) 278-287
57. Martino R., Porras R.P., Rabella N., Williams J.V., Ramila E., Margall N., et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 11 (2005) 781-796
58. Ljungman P., Ward K.N., Crooks B.N., Parker A., Martino R., Shaw P.J., et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 28 (2001) 479-484
59. Roghmann M., Ball K., Erdman D., Lovchik J., Anderson L.J., and Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant 32 (2003) 1085-1088
60. Antinori S., Cascio A., Parravicini C., Bianchi R., and Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 8 (2008) 191-199
61. Sirvent-von Bueltzingsloewen A., Marty P., Rosenthal E., Delaunay P., Allieri-Rosenthal A., Gratecos N., et al. Visceral leishmaniasis: a new opportunistic infection in hematopoietic stem-cell-transplanted patients. Bone Marrow Transplant 33 (2004) 667-668
62. Sepkowitz K.A. Risks and epidemiology of infections after allogeneic hematopoietic stem cell transplantation. In: Bowden R.A., Ljungman P., and Paya C.V. (Eds). Transplant infections. 2nd ed. (2003), Lippincott Williams & Wilkins, Philadelphia 31-38
63. Deeg H.J., and Bowden R.A. Introduction to hematopoietic stem cell transplantation. In: Bowden R.A., Ljungman P., and Paya C.V. (Eds). Transplant infections. 2nd ed. (2003), Lippincott Williams & Wilkins, Philadelphia 3-16
64. Engelhard D., Geller N., and Paterson D.L. Gram-positive and gram-negative infections after hematopoietic stem cell or solid organ transplantation. In: Bowden R.A., Ljungman P., and Paya C.V. (Eds). Transplant infections. 2nd ed. (2003), Lippincott Williams & Wilkins, Philadelphia 225-249
65. Slavin M.A., Osborne B., Adams R., Levenstein M.J., Schoch H.G., Feldman A.R., Meyers J.D., and Bowden R.A. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis. 171 (1995) 1545-1552
66. Goodman J.L., Winston D.J., Greenfield R.A., Chandrasekar P.H., Fox B., Kaizer H., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 326 (1992) 845-851
67. Marr K.A., Seidel K., Slavin M.A., Bowden R.A., Schoch H.G., Flowers M.E., Corey L., and Boeckh M. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow up of a randomized, placebo controlled trial. Blood 96 (2000) 2055-2061
68. Wald A., Leisenring W., van Burik J.A., and Bowden R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175 (1997) 1459-1466
69. Ribaud P., Chastang C., Latgé J.P., Baffroy-Lafitte L., Parquet N., Devergie A., et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis. 28 (1999) 322-330
70. Marr K.A., Carter R.A., Boeck M., Martin P., and Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002) 4358-4366
71. Marr K.A., Carter R.A., Crippa F., Wald A., and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 34 (2002) 909-917
72. Thursky K., Byrnes G., Grigg A., Szer J., and Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004) 115-121
73. Hiemenz J.W., Groll A.H., and Walsh T.J. Infections caused by rare fungi after hematopoietic stem cell or solid organ transplantation. In: Bowden R.A., Ljungman P., and Paya C.V. (Eds). Transplant infections. 2nd ed. (2003), Lippincott Williams & Wilkins, Philadelphia 509-523
74. Boeckh M., Leisenring W., Riddell S.R., Bowden R.A., Haung M.L., Myerson D., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants; importance of viral load and T cell immunity. Blood 101 (2003) 407-414
75. Machado C.M., Dulley F.L., Vilas Boas L.S., Castelli J.B., Macedo M.C.A., Silva R.L., et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy. Bone Marrow Transplant 26 (2000) 413-417
76. Ochs L., Shu X.O., Miller J., Enright H., Wagner J., Filipovich A., et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 86 (1995) 3979-3986
77. Bjorklund A., Ashcan J., Labopin M., Remberger M., Ringden O., Winiarski J., et al. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant 40 (2007) 1055-1062
78. Robin M., Porcher R., De Castro Araujo R., de Latour R.P., Devergie A., Rocha V., et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant. 13 (2007) 1304-1312
79. Styczynski J., Reusser P., Einsele H., de la Camara R., Cordonnier C., Ward K.N., et al. Management of HSV, VZV, and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. (2008) Dec 1. Epub ahead of print. doi: 10.1038/bmt.2008.386
80. Almyroudis N.G., Fuller A., Jakubowski A., Sepkowitz K., Jaffe D., Small T.N., et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematpoietic stem cell transplant recipients. Transpl Infect Dis. 7 (2005) 11-17
81. Reilly A.F., and Lange B.J. Infections with viridians group streptococci in children with cancer. Pediatr Blood Cancer 49 (2007) 774-780
82. Gassas A., Grant R., Richardson S., Dupuis L.L., Doyle J., Allen U., et al. Predictors of viridians streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol. 22 (2004) 1222-1227
83. Prabhu R.M., Piper K.E., Litzow M.R., Steckelberg J.M., and Patel R. Emergence of quinolone resistance among viridians group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis. 24 (2005) 832-838
84. Toro J.J., Morales M., Loberiza F., Ochoa-Bayona J.L., and Freytes C.O. Patterns of use of vascular access devices in patients undergoing hematopoietic stem cell transplantation: results of an international survey. Support Care Cancer 15 (2007) 1375-1383
85. Kim D.H., Bae N.Y., Sung W.J., Kim J.G., Kim S.W., Baek J.H., et al. Hickman catheter site infections after allogeneic stem cell transplantation: a single-center experience. Transplant Proc. 36 (2004) 1579-3
86. Kaufman L.J., Clark T.W., Roberts D.A., Freiman D.B., Shlansky-Goldberg R.D., Patel A.A., et al. Do simultaneous bilateral tunneled infusion catheters in patients undergoing bone marrow transplantation increase catheter-related complications?. J Vasc Interv Radiol. 15 (2004) 57-61
87. Frere P., Hermanne J.P., Debouge M.H., Fillet G., and Beguin Y. Changing patterns of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 29 (2002) 589-594
88. Lau S.K., Woo P.L., Leung K.W., and Yuen K.Y. Emergence of cotrimoxazole- and quinolone resistant Campylobacter infections in bone marrow transplant recipients. Eur J Microbiol Infect Dis. 21 (2002) 127-129
89. Craig M., Crumpston A.P., Hobbs G.R., Devetten M.P., Sarwari A.R., and Ericson S.G. The clinical impact of antimicrobial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant 39 (2007) 477-482
90. Zirakzadeh A., Gastineau D.A., Mandrekar J.N., Burke J.P., Johnston P.B., and Patel R. Vancomycin resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 41 (2008) 385-392
91. Dibo I., Pillai S.K., Gold H.S., Baer H.R., Wetzler M., Slack J.L., et al. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol. 42 (2004) 1843-1845
92. Green M.R., Anasetti C., Sandin R.L., Rolfe N.E., and Greene J.N. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract. 12 (2006) 179-181
93. Kontoyiannis D.P., Lewis R.E., and Marr K. The burden of bacterial and viral infections in hematopoietic stem cell transplant. Biol Blood Marrow Transplant 15 (2009) 128-133
94. Tam V.H., Chang K.T., LaRocco M.T., Schilling A.N., McCauley S.K., Poole K., et al. Prevalence, mechanisms, and risk factors of carbapenem resistance in blood stream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 58 (2007) 309-314
95. Mena A., Plasencia V., Garcia L., Hidalgo O., Ayestaran J.I., Alberti S., et al. Charaterization of a large outbreak by CTX-M-1 producing i and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol. 44 (2006) 2831-2837
96. Poirel L., and Nordmann P. Carbapenem resistance in Acinetobacter baumannii; mechanisms and epidemiology. Clin Microbiol Infect. 12 (2006) 826-836
97. Pournaras S., Iosifidis E., and Roilides E. Advances in antibacterial therapy against emerging bacterial pathogens. Semin Hematol. (2009) (current issue)
98. Kumashi P., Girgawy E., Tarrand J.J., Rolston K.V., Raad I.I., and Safdar A. Streptococcus pneumonia bacteremia in patients with cancer: disease characteristics in the era of escalating drug resistance. Medicine (Baltimore) 84 (2005) 303-312
99. Martino R., Subira M., Rovira M., Solano C., Vazquez L., Sanz G.F., et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 116 (2002) 475-482
100. Marr K.A., Carter R.A., Boeck M., Martin P., and Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002) 4358-4366
101. Thursky K., Byrnes G., Grigg A., Szer J., and Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004) 115-121
102. Trifilio S., Singhal S., Williams S., Frankfurt O., Gordon L., Evens A., et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 40 (2007) 451-456
103. Trifilio S.M., Bennett C.L., Yarnold P.R., McKoy J.M., Parada J., Mehta J., et al. Breakthrough zygomycosis after voriconazole administration among patients with hematological malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 39 (2007) 425-429
104. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., et al. Epidemiology of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 41 (2005) 634-653
105. Kontoyiannis D.P., and Lewis R.E. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 20 (2006) 581-607
106. Marty F.M., Cosimi L.A., and Baden L.R. Breakthrough zygomycosis after voriconazole treatment of recipients of hematopoietic stem cell transplants. N Engl J Med. 350 (2004) 950-952
107. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., Chamilos G., Healy M., Perego C., et al. Zygomycosis in a tertiary-care center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 191 (2005) 1350-1360
108. Groll A.H., and Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol. (2009) (current issue)
109. Wade J.C. Viral infections in patients with hematological malignancies. Hematology [American Society of Hematology Education Program Book]. (2006) 368-374
110. Boeckh M. The challenge of respiratory virus infections in hematopoietic stem cell transplant recipients. Br J Haematol. 143 (2008) 455-467
111. Peck A.J., Englund J.A., Kuypers J., Guthrie K.A., Corey L., Morrow R., et al. Respiratory virus infection among hematopoietic transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 110 (2007) 1681-1688
112. Anaissie E.J., Mahfouz T.H., Aslan T., Pouli A., Desikan R., Fassas A., et al. The natural history of respiratory synctial virus infection in cancer and transplant patients: implications for management. Blood 103 (2004) 1611-1617
113. Giraud G., Priftakis P., Bogdanovic G., Remberger M., Dudrulle M., Hau A., et al. BK-viruria and haemorrhagic cystitis are more frequent in allogeneic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplant 41 (2008) 737-742
114. Giraud G., Bogdanovic G., Priftakis P., Remberger M., Svahn B.M., Barkholt L., et al. The incidence of hemorrhagic cystits and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica 91 (2006) 401-404
115. Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 21 (2008) 704-715
116. Robin M., Marque-Juillet S., Scieux C., Peffault de Latour R., Ferry C., Rocha V., et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica 92 (2007) 1254-1257
117. Zutter M.M., Martin P.J., Sale G.E., Shulman H.M., Fisher L., Thomas E.D., et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72 (1988) 520-529
118. Sundin M., Le Blanc K., Ringden O., Barkholt L., Omazic B., Lergin C., et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Hematologica 91 (2006) 1059-1067
119. Brunstein C.G., Weisdorf D.J., DeFor T., Barker J.N., Tolar J., van Burik J.A., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108 (2006) 2874-2880
120. Chakrabarti S., Pillay D., Ratcliffe D., Cane P.A., Collingham K.E., and Milligan D.W. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis. 181 (2000) 2055-2058
121. Chen Y., Scieux C., Garrait V., Socie G., Rocha V., Molina J.M., et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis. 31 (2000) 927-935
122. Erard V., Wald A., Corey L., Leisenring W.M., and Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug resistant HSV disease. J Infect Dis. 196 (2007) 266-270
123. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 56 RR04 (2007) 1-40
124. Boeckh M.J., and Ljungman P. Cytomegalovirus infection after hematopoietic stem cell transplantation. In: Bowden R.A., Ljungman P., and Paya C.V. (Eds). Transplant Infections. 2nd ed. (2003), Lippincott Williams & Wilkins, Philadelphia 277-297
125. Kollmon C., Howe C.W., Anasetti C., Antin J.H., Davies S.M., Filipovich A.H., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98 (2001) 2043-2051
126. Junghanss C., Boeckh M., Carter R.A., Sandmaier B.M., Maris M.B., Maloney D.G., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99 (2002) 1978-1985
127. Xhaard A., Robin M., Scieux C., de Latour R.P., Deplus S., Mazeron M.C., et al. Increased incidence of cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation. Transplantation 83 (2007) 80-83
128. Laarson K., Lonnqvist B., Ringden O., Hedquist B., and Ljungman P. CMV retintitis after allogeneic bone marrow transplantation: a report of five cases. Transpl Infect Dis. 4 (2002) 75-79
129. Crippa F., Corey L., Chuang E.L., Sale G., and Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 32 (2001) 214-219
130. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., and Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83 (1994) 1971-1979
131. Reed E.C., Wolford J.L., Kopecky K.J., Lilleby K.E., Dandliker P.S., Todaro J.L., et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized placebo-controlled trial. Ann Intern Med. 112 (1990) 505-510
132. Ljungman P., Cordonnier C., Einsele H., Bender-Gotze C., Bosi A., Dekkar A., et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 21 (1998) 473-476
133. Meijer E., Slaper-Cortenbach I.C., Thijsen S.F., Dekkar A.W., and Verdonck L.F. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell deplection technique. Bone Marrow Transplant 29 (2002) 335-339
134. Kinch A., Oberg G., Arvidson J., Linde A., and Pauksens K. Post transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic stem cell transplantation after introduction of monitoring viral load by polymerase chain reaction. Scand J Infect Dis. 39 (2007) 235-244
135. Aalto S.M., Juvonen E., Tarkkanen J., Volin L., Haario H., Ruutu T., et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis. 45 (2007) 1305-1309
136. + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 101 (2003) 4290-4297
137. Annels N.E., Kalpoe J.S., Bredius R.G., Claas E.C., Kroes A.C., Hislop A.D., et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconsititution. Clin Infect Dis. 42 (2006) 1743-1748
138. Zerr D.M., Corey L., Kim H.W., Huang M.L., Nguy L., and Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 40 (2005) 932-940
139. Ogata M., Kikuchi H., Satou T., Kawano R., Ikewaki J., Kohono K., et al. Human herpes virus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis. 193 (2006) 68-79
140. Kamble R.T., Clark D.A., Leong H.N., Heslop H.E., Brenner M.K., and Carrum G. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 40 (2007) 563-566
141. Visser A.M., van Doorman G.J., Cornelissen J.J., and van den Bent M.J. Severe amnesia due to HHV-6 encephalitis after allogeneic stem cell transplant. Eur Neurol. 54 (2005) 233-234
142. Wang L.R., Dong L.J., Zhang M.J., and Lu D.P. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12 (2006) 1031-1037
143. Hentrich M., Oruzio D., Jager G., Schemmer M., Schleuning M., Schiel X., et al. Impact of human herpesvirus-6 after hematopoietic stem cell transplantation. Br J Haematol. 128 (2005) 66-72
144. Pohlmann C., Shetelig J., Reuner U., Bornhauser M., Illmer T., Kiani A., et al. Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient. Clin Infect Dis. 44 (2007) e118-e120
145. Ogata M., Satou T., Kawano R., Goto K., Ikewaki J., Kohno K., et al. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantion: a prospective evaluation. Bone Marrow Transplant 41 (2008) 279-285
146. Boutolleau D., Fernandez C., Andre E., Imbert-Marcille B.M., Milpied N., Agut H., and Gautheret-Dejean A. Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients. J Infect Dis. 187 (2003) 179-186
147. Ward K.N., White R.P., Mackinnon S., and Hanna M. Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient. Bone Marrow Transplant 30 (2002) 983-985
148. Bruno B., Sorasio R., Barozzi P., Vieira J., Omede P., Giaretta F., et al. Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation. Eur J Haematol. 76 (2006) 342-347
149. Luppi M., Barozzi P., Rasini V., and Torelli G. HHV-8 infection in the transplant setting: a concern only for solid organ transplant patients?. Leuk Lymphoma 43 (2002) 517-522
150. Muller W.J., Levin M.J., Shin Y.K., Robinson C., Quinones R., Malcolm J., et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis. 41 (2005) 1812-1816
151. Fanourgiakis P., Georgala A., Vekemans M., Triffet A., De Bruyn J.M., Duchateau V., et al. Intravesicular instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. Clin Infect Dis. 40 (2005) 199-201
152. Neofytos D., Ojha A., Mookerjee B., Wagner J., Filicko J., Ferber A., et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 13 (2007) 74-81
153. Dropulic L.K., and Jones R.J. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant 41 (2008) 11-18
154. Green M., Ljungman P., and Michaels M.G. Adenovirus, parvovirus B19, papilloma virus, and polyomaviruses after hematopoietic stem cell or solid organ transplantation. In: Bowden R.A., Ljungman P., and Paya C.V. (Eds). Transplant infections. 2nd ed. (2003), Lippincott Williams & Wilkins, Philadelphia 399-411
155. Erard V., Storer B., Corey L., Nollkamper J., Huang M.L., Limaye A., and Boeckh M. BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors and association with post engraftment hemorrhagic cystitis. Clin Infect Dis. 39 (2004) 1861-1865
156. Bridges B., Donegan S., and Badros A. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. Am J Hematol. 81 (2006) 535-537
157. Savona M.R., Newton D., Frame D., Levine J.E., Mineishi S., and Kaul D.R. Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant 39 (2007) 783-787
158. Lekakis L.J., Macrinici V., Baraboutis I.G., Mitchell B., and Howard D.S. BK virus nephropathy after allogeneic transplantation: a case report and literature review. Am J Hematol 84 (2009) 243-246
159. Leung A.Y.H., Chan M.T.L., Yeun K.Y., Cheng V.C.C., Chan K.H., Wong C.L.P., et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 40 (2005) 528-537
160. Behre G., Becker M., and Christopeit M. BK virus encephalitis in an allogeneic hematopoietic stem cell recipient. Bone Marrow Transplant 42 (2008) 499
161. Englund J.A., Boeckh M., Kupyers J., Nichols W.G., Hackman R.C., Morrow R.A., et al. Brief communication:fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 144 (2006) 344-349
162. Nauseff W.N., and Maki D.G. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med. 304 (1981) 448-453
163. Pizzo P.A. Do the results justify the expense of protected environments?. In: Weirnik P. (Ed). Controversies in oncology (1982), John Wiley & Sons, New York 267-277
164. Dykewicz C.A. Hospital infection control in hematopoietic stem cell transplant recipients. Emerg Infect Dis. 7 (2001) 263-267
165. Peterson F., Thornquist M., Buckner C., et al. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study. Infection 16 (1988) 188-208
166. Slavin M.A., Grigg A.P., Schwarer A.P., Szer J., Spencer A., Sainani A., et al. A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. Bone Marrow Transplant 40 (2007) 157-163
167. Winston D.J., Maziarz R.T., Chandrasekar P.H., Lazarus H.M., Goldman M., Blumer J.L., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long term prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med. 138 (2003) 705-713
168. Marr K.A., Crippa F., Leisenring W., Hoyle M., Boeckh M., Balajee S.A., et al. Intraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplantations. Blood 103 (2004) 1527-1533
169. van Burik J.H., Ranathanatharathorn V., Stephan D.E., Miller C.B., Lipton J., Vesole D.H., et al. Micafungin versus fluconazole for prophylaxis of invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 39 (2004) 1407-1416
170. Hiemenz J., Cagnoni P., Simpson D., Devine S., Choa N., Keirns J., et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole in versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother. 49 (2005) 1331-1336
171. Hamza N.S., Ghannoum M.A., and Lazarus H.M. Changes a plenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 34 (2004) 377-389
172. Wingard J.R., Carter S.L., Walsh T.J., Kurtzberg J., Small T.N., Gersten I.D., et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. [abstract]. Blood 110 (2007) 163
173. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
174. De Castro N., Neuville S., Sarfati C., Ribaud P., Derouin F., Gluckman E., et al. Occurrence of Pneumocystis jirovoeci pneumonia after allogeneic stem cell transplantation: a 6 year retrospective study. Bone Marrow Transplant 36 (2005) 879-883
175. Worth L.J., Dooley M.J., Seymour J.F., Mileshkin L., Slavin M.A., and Thursky K.A. An analysis of the utilization of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 92 (2005) 867-872
176. Colby C., McAfee S.L., Sackstein R., Finkelstein D.M., Fishman J.A., and Spitzer T.R. A prospective randomized trial comparing toxicity and safety of atovaquone following with trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplant. Bone Marrow Transplant 24 (1999) 897-902
177. Souza J.P., Boeckh M., Gooley T.A., Flowers M.E., and Crawford S.W. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients following dapsone prophylaxis. Clin Infect Dis. 29 (1999) 1467-1471
178. Marras T.K., Sanders K., Lipton J.H., Messner H.A., Conly J., and Chan C.K. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic transplantation. Transpl Infect Dis. 4 (2002) 66-74
179. Vasconcelles M.J., Bernardo M.V., King C., Weller E.A., and Antin J.H. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 6 (2000) 35-43
180. Machado C.M., Macedo M.C.A., Medeiros R.S.S., Massumoto C., Silva A.C.M., Castella J.B., et al. Primary Pneumocysts carinii prophylaxis with aerosolized pentamidine after bone marrow transplantation. Acta Haematol. 99 (1998) 54-56
181. Winston D.J., Young J.H., Pullarkat V., Papanicoloau G.A., Vij R., Vance E., et al. Maribivar prophylaxis for prevention of CMV infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo controlled, dose ranging study. Blood 111 (2008) 5403-5410
182. Boeckh M., Nichols G., Chemaly R., Papanicolaou G., Wingard J., Kirby K.A., et al. Prevention of late CMV disease after HCT: a randomized double-blind multicenter trial of valganciclovir (VGCV) prophylaxis versus PCR-guided GCV/VGCV preemptive therapy. Biol Blood Marrow Transplant. 14 (2008) 30
183. Hobeika A., Osada T., Serra D., Peplinski S., Hanson K., Tanaka Y., et al. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. Cytotherapy 10 (2008) 289-302
184. Hakki M., Riddell S.R., Storek J., Carter R.A., Stevens-Ayers T., Sudour P., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical infection. Blood 102 (2003) 3060-3067
185. Levy J.B., and Pusey C.D. Nephrotoxicity of intravenous immunoglobulin. Q J Med. 93 (2000) 751-755